1. Pharmacokinetics and bioavailability of zidovudine in humans;Blum;Am. J. Med.,1988
2. Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers;Breen;Antimicrob. Agents Chemother.,1994
3. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201-E) in combination with zidovudine or didanosine;Campbell;J. Infect. Dis.,1993
4. Cox, S.R., Batts, D.H., Dietz, A.J., Hanover, C.K., Peel, B.G., Elfring, G.L., 1992. A phase I multiple dose study of U-87201E, a non-nucleoside RT inhibitor in normal healthy males. VIII Int. Conf. on AIDS, Amsterdam, Netherlands, 19–24 July 1992.
5. Demeter, L.M., Resnick, L., Nawaz, T., Timpone, J.G., Batts, D., Reichman, R.C., 1993. Phenotypic and genotypic analysis of atevirdine susceptibility of HIV-1 isolates obtained from patients receiving atevirdine monotherapy in a phase I clinical trial (ACTG 187): comparison to patients receiving combination therapy with atevirdine and zidovudine. 3rd Workshop on Viral Resistance. Gaithersburg, MD, September, 1993.